May16Tue
Forbes ranking of top employers drawn from a survey of 30,000 US employees in 25 industry sectors
Dublin, Ireland, 11 May 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been included in Forbes magazine’s America’s Best Employers list for 2017.
Now in its third year, the Forbes list features the top 500 large employers in the US with more than 5,000 employees and the top 300 midsize companies with 1,000 – 5,000 employees. ICON was the highest ranked CRO in the best midsize employers listing. Read More
Inhibitors of Wee-1 kinase, cell cycle regulator, have potential for clinical utility across a broad range of cancer indications
Craigavon, N.I., UK, 08 May 2017 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced that the United States Patent and Trademarks office (USPTO) has granted patent protection for a key patent family for its Wee-1 kinase inhibitor programme.
May05Fri
IABCN Board members, Kevin Kent, Sean Flatley and Christine Hartmann, travelled to the Irish Consulate in New York City on May 5th to join the American Chamber of Commerce Ireland in celebrating the US launch of the Irish-US Economic Relationship 2017 Report. To read the entire report, please click HERE.
Mary Mitchell O’Connor, TD, Minister of Jobs, Enterprise and Innovation gave an address on the reciprocal nature of the Irish-America relationship. Also present was Olympic Medalist Annalise Murphy who won the Silver in the 2016 Olympics in Rio for sailing.
Congratulations were bestowed on Galway man, Gavin Henningan, who finished third and set a new Irish record for rowing across the Atlantic in the Talisker Whiskey challenge in under 50 days. He rowed from the Canary Islands to Antigua.
Apr28Fri
Dublin, Ireland, April 27, 2017 – ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2017.
Gross business wins in the first quarter were $580 million and cancellations in the quarter were $59 million, resulting in net business wins of $521 million, a net book to bill of 1.21.
– In the first quarter net revenue grew 7.8% year on year to $432 million from $400.5 million in the same quarter last year.
– Income from operations increased by 12.7% to $85.7 million, or 19.8% of revenue, compared to $76.0 million or 19.0% for the same quarter last year.
– Net income in the quarter increased by 13.4% to $71.4 million compared with $63.0 million in the same quarter last year.
– Earnings per share increased to $1.29 per share on a diluted basis, from $1.12 per share for the same quarter last year, an increase of 15.2%.
– Day’s sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 47 days at March 31, 2017, compared with 50 days at the end of December 31, 2016 and 47 days at the end of March 2016.
